Shin Nippon Biomedical Laboratories, Ltd.

Wave Life Sciences Japan, Inc.

Anges Mg, Inc.

Funpep Inc.

Rush University Medical Center

Takefumi Gemba

Hideki Tomioka

Nao Tamura

Ryuichi Morishita

Ryoichi Nagata

Akiko Tenma

Ryoko Sata

Akito Maeda

Toshihide Kanamori

Yoshimi Saito

Shintaro Komaba

Koichi Masuda

Yusuke Torikai

Ikumi Shiga

Problem To provide a chiral nucleic acid adjuvant and anti-allergic agent having anti-allergic effect. Solution An adjuvant which comprises oligonucleotides which comprise two to four CpG motifs each represented by 5'-XCpGX-3&#x2032; and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3&#x2032; end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3&#x2032; end and 5&#x2032; end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an adjuvant comprising the oligonucleotide represented by the sequence number 67. The present invention relates to an anti-allergic agent comprising these adjuvant.

Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent

Summary Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having anti-tumor activity; and an anti-tumor agent. Solution The present invention relates to an adjuvant for anti-tumor agent, wherein the adjuvant comprises oligonucleotides which comprise two to four CpG motif each represented by 5'-XCpGX-3&#x2032; and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3&#x2032; end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acid at 3&#x2032; end and 5&#x2032; end of the oligonucleotide is S type nucleic acid connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an anti-tumor agent containing its adjuvant.

Chiral nucleic acid adjuvant having antitumor effect and antitumor agent

Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having immunity-inducing activity and an immunity-inducing activator. Solution The present invention relates to an adjuvant which comprises oligonucleotides which comprise two to four sequences each represented by 5'-XCpG X-3&#x2032; and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3&#x2032; end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3&#x2032; end and 5&#x2032; end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an immunity-inducible activator comprising the adjuvant.

Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator

A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.

Polypeptide having antibacterial activity and angiogenesis-inducing activity and wound-healing drug containing said polypeptide

Problem The purpose of the present invention is to provide: a stereo isomer of a novel CpG oligonucleotide, which has excellent stability; and a CpG oligonucleotide which has a capability of producing interferon-&#x3b1; (IFN&#x3b1;). Solution The present invention relates to an oligonucleotide which contains two to four sequences each represented by the formula 5'-XXCpGXX-3&#x2032; (formula (I)) and has a length of 14 to 32 nucleotides. In formula (I), CpG represents a non-methylated CpG residue having a phosphate skeleton modification, XXrepresents any one of AA, AT, GA and GT, and XXrepresents any one of TT, AT, AC and CG. The oligonucleotide has at least one phosphate skeleton modification at an S-form stereoisomer located at a site other than the CpG.

Chiral nucleic acid adjuvant

Novel polypeptides which have an excellent angiogenesis-inducing activity and an excellent antibacterial activity and medical uses thereof are disclosed. The amino acid sequences of the novel polypeptides are shown in any one of SEQ ID NOs:1 to 6. These polypeptides have angiogenesis-inducing and antibacterial activities. Such polypeptides are useful for the prevention, amelioration or treatment of skin wounds caused by a cut wound, surgical wound, erosion, burn, decubitus, intractable wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease or arteriosclerosis obliteran, and for the prevention, amelioration or treatment of bacterial infection in such skin wounds, and the like.

Polypeptide having angiogenesis-inducing activity and antibacterial activity, and use thereof for medical purposes

A novel polypeptide, and an antibacterial agent, antifungal agent and/or antiseptic containing as an effective ingredient the polypeptide are disclosed. The polypeptide of this invention has an amino acid sequence shown in SEQ ID NOs:1 to 12 and 13 to 31. This antibacterial agent, antifungal agent and/or antiseptic is useful for the prevention, amelioration or treatment of diseases such as burn, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliterans, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, skin abscess, necrotizing subcutaneous infection, staphylococcal scalded skin syndrome (SSSS), folliculitis, facial furuncle, suppurative hidradenitis, carbuncle, infectious paronychia, erythrasma and severe infection (sepsis).

Polypeptides and antibacterial or antiseptic use of same

Described herein are methods and compositions for inhibiting, treating and reversing intervertebral disc disorders using transcription factor inhibitors. In certain embodiments, the transcription factor inhibitor targets the transcription factor NF-&#x3ba;B. Also described are methods and compositions where intervertebral disc disorder is reversed using a decoy oligodeoxy-nucleotide that blocks NF-&#x3ba;B.

Growing community of inventors

Kawanishi, Japan

Takefumi Gemba